Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen 4Q

Product sales were up 2% to $3.7 billion in 4Q09.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 4Q

4Q Revenues: $3.8 billion (+2%)

4Q Earnings: $931 million (+1%)

FY Revenues: $14.6 billion (-2%)

FY Earnings: $4.6 billion (+14%)

Comments: Product sales were up 2% to $3.7 billion in 4Q09. Sales in the U.S. were $2.9 billion (-1%) for the quarter, while International sales were up 11% to $861 million. Foreign exchange positively impacted 4Q09 sales by $35 million. Worldwide sales of Aranesp were $648 million in the quarter (-8%). Sales of Epogen were up 9% to $703 million. Combined worldwide sales of Neulasta and Neupogen were $1.2 billion (+2%). Sales of Enbrel in the quarter were flat at $912 million. Worldwide sales of Sensipar were $171 million (+12%). Vectibix sales for the quarter were $66 million (+43%). For the year, total product sales were $14.4 billion (-2%). U.S. sales for year totaled $11.1 billion (-3%). International sales were flat at $3.2 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters